30,180 Alzheimer's and dementia studies in plain English, each scored out of 100.
Dementia with Lewy bodies (DLB) is a common neurodegenerative dementia that remains difficult to distinguish clinically from Alzheimer's disease (AD) and related disorders because of overlapping clinical features and frequent mixed pathology. 4 key findings →
Participants: 20 Evidence: low
Full summary, score breakdown and related studies → Original source
The defining neuropathologic feature of Lewy body dementia (LBD) and Parkinson’s disease (PD) is alpha-synuclein (Asyn) fibril accumulation in Lewy bodies (LBs) and Lewy neurites (LNs). 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Seeding readouts correlated with Hoehn and Yahr stage but not significantly with MoCA score or pS129 α-synuclein burden. 1 key finding →
Evidence: moderate
Full summary, score breakdown and related studies → Original source
Neuroinflammation is a hallmark of several chronic neurodegenerative disorders, including Parkinson’s disease (PD) and other synucleinopathies, and is closely associated with microglial activation. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Mutations in GRN and C9orf72 are common causes of frontotemporal dementia (FTD). 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Forty‑two studies published between 1997 and 2025 were included. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Recorded PD-related mortality was lower among Black than White adults, whereas AD-related mortality showed no statistically significant racial difference. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Symptom chronology emerged as a robust diagnostic discriminator, underscoring the clinical value of temporal disease trajectories. 3 key findings →
Participants: 932 Evidence: low
Full summary, score breakdown and related studies → Original source
Affective symptoms, such as depression, anxiety and apathy, are highly prevalent in cognitively impaired Lewy body disease (LBD) groups, including Parkinson’s disease dementia and dementia with Lewy bodies. 2 key findings →
Design: systematic review Participants: 785 Evidence: high
Full summary, score breakdown and related studies → Original source
Parkinson’s disease (PD) progression is highly heterogeneous. 2 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source
A bstract In this study, we build EEG based graph model that uses frequency-resolved connectivity features, with Coherence, phase locking value (PLV) and phase lag index (PLI) in five frequency bands as multi-dimensional edge features. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
The observed protective effect may be explained by vascular and neuroprotective mechanisms unique to PDE5 inhibitors. 4 key findings →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source
We identified 27 phenotypes associated with APOE, mainly in neurological and lipid-related traits. 5 key findings →
Participants: 181,880 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Formalin-fixed, paraffin-embedded (FFPE) brain tissue is a major archival resource, yet its suitability for high-density DNA methylation profiling is limited by fixation-induced DNA fragmentation and crosslinking. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
TAR DNA-binding protein 43 (TDP-43) is a key pathological hallmark of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) and a critical regulator of RNA splicing. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
White matter hyperintensities (WMHs) are a hallmark of cerebral small vessel disease, commonly seen in cognitively normal older adults and patients with neurodegenerative disorders, and are thought to reflect varying degrees of tissue damage. 2 key findings →
Participants: 45 Evidence: low
Full summary, score breakdown and related studies → Original source
Arterial spin labelling (ASL) MRI provides a noninvasive measure of cerebral perfusion, raising the possibility of distinguishing Parkinson's disease (PD) from atypical parkinsonian syndromes (corticobasal syndrome, multiple system atrophy, progressive supranuclear palsy) and of separating the associated cognitive disorders, PD dementia and dementia with Lewy bodies (DLB), from Alzheimer's disease (AD). 5 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source
Frontotemporal dementia (FTD) caused by progranulin (GRN) mutations is associated with pronounced thalamic degeneration, yet the cellular basis of selective thalamic vulnerability remains poorly understood. 3 key findings →
Participants: 92 Evidence: low
Full summary, score breakdown and related studies → Original source
The theta/alpha ratio is a promising but specification-dependent marker of cognitive impairment, contingent particularly on ICA and spectral power quantification. 4 key findings →
Participants: 49 Evidence: low
Full summary, score breakdown and related studies → Original source
Face processing abilities are critical for social interaction, yet impairments are common across dementia syndromes and constitute a core diagnostic feature of some neurocognitive disorders. 5 key findings →
Design: systematic review Participants: 3,810 Evidence: high
Full summary, score breakdown and related studies → Original source
Frontotemporal lobar degeneration (FTLD) is a common cause of early-onset dementias marked by progressive declines in behavior, cognition, and/or movement. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Structured Abstract INTRODUCTION Tau pathology typically occurs in Alzheimeŕs disease (AD), however is also frequently present in Parkinsońs disease dementia (PDD) and Dementia with Lewy Bodies (DLB), yet its disease-specific signature is unclear. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Approximately 90% of Parkinson's disease (PD) patients exhibit olfactory deficits, which often precedes motor symptoms by years, and are a robust predictor for PD and subsequent cognitive decline. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Isolated rapid eye movement sleep behaviour disorder (iRBD) strongly predicts future Lewy body disease and identifies a more aggressive, non-motor phenotype in Parkinson’s disease (PD). 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Parkinson’s disease (PD) exhibits considerable variability in symptom onset, severity, and clinical trajectories, making prediction of individual disease progression a complex challenge. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
10 of the 2,748 studies in this tag that have a study page, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 30,180 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 30,180 records, built mostly from automated pulls of Europe PMC (64.2% of the library) and OpenAlex (16.9%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,037 records (3.4% of the library) are not peer-reviewed — 964 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →